MIAMI, April 7, 2026 /PRNewswire/ -- Florida International University and Herbert Wertheim College of Medicine (FIU Medicine) today announced a landmark $30 million gift from philanthropists Helen and Jacob Shaham. In recognition of their generosity, the academic medical center currently under construction on FIU's main campus, in partnership with Baptist Health South Florida (Baptist Health), will be named the Helen and Jacob Shaham Academic Medical Center. Continue Reading Pictured L to R: Dr

Former Hologic executive to lead next phase of growth and commercial execution for medical technology leader CARLSBAD, Calif., April 7, 2026 /PRNewswire/ -- ImpediMed, a leader in the development and commercialization of medical technologies to clinically monitor and manage fluid and body composition, and its Board of Directors have announced the appointment of Erik Anderson as Managing Director and Chief Executive Officer. Anderson, who joined the company's Board of Directors in February 2026,

PARSIPPANY, N.J., April 7, 2026 /PRNewswire/ -- Dexcel Pharma USA is pleased to announce that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, 100 mg and 150 mg, the generic equivalent of OFEV® (nintedanib) capsules1. Nintedanib is indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a serious and progressive lung disease. Continue Reading Nintedanib Capsules Doug Boothe, CEO o

ALISO VIEJO, Calif., April 7, 2026 /PRNewswire/ -- Okami Medical, a medical technology company pioneering novel vascular embolization solutions, today announced the enrollment of the first patient in the ALPHA Registry, a prospective, multicenter registry evaluating the safety and effectiveness of the LOBO™ Vascular Occlusion System for patients suffering from a variety of peripheral vascular conditions, including arterial hemorrhage and pulmonary arteriovenous malformation. "We are honored to e

—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose of Brensocatib— BRIDGEWATER, N.J., April 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the Phase 2b

Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within Their Existing Patient Portal Collaboration With Epic Will Allow Clinicians to Seamlessly Order the Galleri Multi-Cancer Early Detection Test at the Point of Care MENLO PARK, Calif., April 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Epic to bring the Galleri® multi-cancer

New evidence-based guidelines establish insufficient evidence or no benefit to dietary or environmental interventions ROSEMONT, Ill., April 7, 2026 /PRNewswire/ -- For the first time in its history, the American Academy of Dermatology (AAD) has published guidelines of care for both the prevention and management of atopic dermatitis (commonly known as eczema) in pediatric patients. While pediatric and adult eczema share similarities, these guidelines recognize the unique safety, dosing, and patie

Patients seek trusted providers for clarity in a complex health information landscape AUSTIN, Texas, April 7, 2026 /PRNewswire/ -- Americans are turning to the internet and artificial intelligence (AI) in record numbers for health information. But many are unsure whether what they find is accurate or trustworthy, according to a new national survey released by the American Association of Nurse Practitioners® (AANP). Continue Reading The number of Americans using AI tools to search up healthcare i

THE BIZARRE MEDICAL BILLING CODES THAT REVEAL HOW AMERICANS ACTUALLY LIVE - WHAT IT COSTS WHEN THEY GO WRONG, AND HOW AI IS FINALLY FIXING IT NEW YORK and COPENHAGEN, Denmark, April 7, 2026 /PRNewswire/ -- Every time a patient sees a doctor, the symptoms, procedures and diagnoses need to be translated into standardized labels chosen from tens of thousands of possibilities. In the United States, that list has 72,000 options. These labels are called medical codes. They determine whether the hosp

SAN DIEGO, April 7, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today the initiation of the dose expansion phase in their clinical study evaluating spevatamig in combination with chemotherapy for the treatment of biliary tract cancer (BTC), following dose-limiting toxicity (DLT) clearance at two dose levels. Spevatamig is a first-in-class native IgG-like bispecific antibody (